Anthropic’s April 14 X post matters because it says something about governance, not just recruiting. The company says its Long-Term Benefit Trust has appointed Novartis CEO Vas Narasimhan to the board, adding a regulated-industry operator at a moment when frontier AI labs are under pressure to prove they can scale powerful systems without losing control of deployment. In Anthropic’s case, the move also shifts the balance of the board itself.

‘Our Long-Term Benefit Trust has appointed Vas Narasimhan to Anthropic’s Board of Directors. Vas brings more than two decades of experience in medicine and global health…’ Source tweet

The linked Anthropic note explains why the hire is more than a headline-friendly name. The company says Narasimhan is a physician-scientist and the CEO of Novartis, and that he has overseen the development and approval of more than 35 novel medicines. Anthropic also says his appointment means trust-appointed directors now make up a majority of the board. For a public benefit corporation that has spent years arguing its governance structure is part of its safety story, that is a material shift rather than a ceremonial addition. The full note is here.

The @AnthropicAI account usually alternates between model research, product rollouts, and policy messaging. This post sits squarely in the governance lane. Anthropic frames healthcare and life sciences as areas where AI could materially improve quality of life, and Narasimhan’s background is tailored to that argument. The company highlights his work in global health and his leadership in one of the world’s most regulated innovative-medicines businesses. That gives Anthropic a board member who has already spent years dealing with high-stakes science, safety review, and scaled deployment under scrutiny.

The next thing to watch is whether this board change shows up in strategy, especially around healthcare, life sciences, and the way Anthropic talks about responsible scaling. Governance is easy to dismiss when product launches dominate the news cycle, but it becomes important when labs start making decisions about where powerful systems can be deployed first. This appointment suggests Anthropic wants regulated-industry judgment closer to the center of those calls.

#novartis

Anthropic adds Novartis CEO as trust-appointed directors take board majority